CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
干细胞移植与细胞治疗中的肺部免疫功能受损
英文原题：Pulmonary Immunocompromise in Stem Cell Transplantation and Cellular Therapy.
查看英文原题
Pulmonary Immunocompromise in Stem Cell Transplantation and Cellular Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
造血细胞移植（HCT）和细胞疗法，如CAR-T 细胞治疗，是某些血液系统恶性肿瘤和一些非恶性疾病的潜在治愈性治疗方法。然而，感染性和非感染性肺部并发症仍然是接受细胞疗法患者发病和死亡的重要原因。这篇综述文章概述了在HCT和CAR-T 背景下遇到的肺部并发症。作者讨论了导致感染增加的潜在免疫受损机制。此外，他们强调了HCT的关键非感染性并发症，这些并发症可能模仿急性感染，并提出了诊断方法和预防策略，以及时区分这些疾病。
展开英文摘要原文
Hematopoietic cell transplantation (HCT) and cellular therapies, such as chimeric-antigen receptor T-cell (CAR-T) treatments, are potentially curative treatments for certain hematologic malignancies and some nonmalignant disorders.
However, pulmonary complications, both infectious and noninfectious, remain a significant cause of morbidity and mortality in patients who receive cellular therapies. This review article provides an overview of pulmonary complications encountered in the context of HCT and CAR-T. The authors discuss mechanisms of underlying immunocompromise that lead to a rise in infections.
Additionally, they highlight key noninfectious complications of HCT that can mimic acute infections and suggest diagnostic approaches and preventive strategies to distinguish these entities promptly.
论文信息
- 作者
- Mir M、Faiz S、Bommakanti AG、Sheshadri A
- 第一作者单位
- Divisions of Critical Care, Pulmonary and Sleep Medicine, McGovern Medical School at UTHealth, Houston, TX 77030, USA; Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.United States
- 通讯作者单位
- Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: asheshadri@mdanderson.org.United States
- 文献类型
- 综述
- 期刊
- Clinics in chest medicine2025 Mar
- 原文标识
- PubMed 39890284 · DOI 10.1016/j.ccm.2024.10.010